JPS5798218A - Production of adjuvant-active substance - Google Patents

Production of adjuvant-active substance

Info

Publication number
JPS5798218A
JPS5798218A JP16954881A JP16954881A JPS5798218A JP S5798218 A JPS5798218 A JP S5798218A JP 16954881 A JP16954881 A JP 16954881A JP 16954881 A JP16954881 A JP 16954881A JP S5798218 A JPS5798218 A JP S5798218A
Authority
JP
Japan
Prior art keywords
substance
cmi
treated
acid
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP16954881A
Other languages
Japanese (ja)
Other versions
JPS58410B2 (en
Inventor
Ichiro Azuma
Yuichi Yamamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP16954881A priority Critical patent/JPS58410B2/en
Publication of JPS5798218A publication Critical patent/JPS5798218A/en
Publication of JPS58410B2 publication Critical patent/JPS58410B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PURPOSE: D-CMI-A substance is treated with an acid to produce the titled D- CMI-B substance with reduced side-effects.
CONSTITUTION: The wax D substance is treated with a polar solvent such as methanol, acetone, chloroform-methanol mixed solvent at room or elevated temperature. The resultant D-CMI substance is treated with a protease such as tripsin, chymotripsin or pronase to remove substances causing allergic reactions such as tuberculin protein and give D-CMI-A substance. The D-CMI-A substance is treated with an acid such as periodic acid or periodate salt in solvent such as water or ethanol to give the D-CMI-B substance. The wax D substance contains mycolic acid, arabinogalactan and mucopeptide as the base structure and is obtained from cell bodies of a bacterium such as Mycobacterium.
EFFECT: The resultant substance causes no allergic shock, since it is free from antibiotics, and has the same level of adjuvant and anticancer activites as that of the D-CMI-A substance.
COPYRIGHT: (C)1982,JPO&Japio
JP16954881A 1981-10-22 1981-10-22 Method of manufacturing adjuvant active substances Expired JPS58410B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16954881A JPS58410B2 (en) 1981-10-22 1981-10-22 Method of manufacturing adjuvant active substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16954881A JPS58410B2 (en) 1981-10-22 1981-10-22 Method of manufacturing adjuvant active substances

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2880174A Division JPS5729449B2 (en) 1974-03-12 1974-03-12

Publications (2)

Publication Number Publication Date
JPS5798218A true JPS5798218A (en) 1982-06-18
JPS58410B2 JPS58410B2 (en) 1983-01-06

Family

ID=15888510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16954881A Expired JPS58410B2 (en) 1981-10-22 1981-10-22 Method of manufacturing adjuvant active substances

Country Status (1)

Country Link
JP (1) JPS58410B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025758A1 (en) * 2015-08-13 2017-02-16 Diagnostig Ltd Compositions and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025758A1 (en) * 2015-08-13 2017-02-16 Diagnostig Ltd Compositions and methods
US10782293B2 (en) 2015-08-13 2020-09-22 Diagnostig Ltd Compositions and methods

Also Published As

Publication number Publication date
JPS58410B2 (en) 1983-01-06

Similar Documents

Publication Publication Date Title
JPS51139831A (en) Primer composition
JPS568320A (en) Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS5294487A (en) Production of compositions containing enzyme or microbial cells
JPS5798218A (en) Production of adjuvant-active substance
EP0146239A3 (en) Bioconversion production of ascorbic acid
JPS53139791A (en) Preparation of 7-aminocephem compounds
ES541593A0 (en) PROCEDURE FOR PREPARING N1-METHYL-10-METOXYLUMYLISERGOL
DK169387A (en) Guar MEL
JPS5275134A (en) Electric charge transfer device
JPS5210486A (en) Isolation of urokinase
JPS5798217A (en) Production of adjuvant active substance
JPS5238097A (en) Manufacture of vinegar
JPS5238083A (en) Method of producing penicillinase
JPS5283940A (en) Immuno-inhibitor
JPS52151440A (en) Thrust bearing
JPS52133915A (en) Separation method of fructose
JPS5217605A (en) Float type small commutating motor
JPS5718619A (en) Tumor immunotherapy agent containing lipopolysaccharide as active principle
JPS5239852A (en) Heat exchange plant
JPS531413A (en) Mixing circuit
JPS51125362A (en) Process for synthesizing echinatin glycosides
JPS5243053A (en) Static pressure bearing
JPS5251088A (en) Culture of basidiomycetes
JPS51129491A (en) Method of manufacturing polyesters
JPS5229662A (en) Low temperature crushing method